Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.28
-0.2%
$5.95
$4.35
$12.38
$315.70M0.43209,378 shs1.31 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.41
+1.6%
$6.36
$4.58
$9.78
$371.54M1.85514,411 shs1.89 million shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$1.19
-6.3%
$1.52
$0.99
$5.77
$75.08M1.66842,981 shs9.53 million shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$10.68
-6.8%
$10.47
$8.46
$28.83
$277.15M0.33110,443 shs300,629 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
0.00%+3.97%+7.53%+7.17%-16.93%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.33%+22.28%+21.88%+7.24%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
0.00%-9.16%-13.20%-6.30%-72.00%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
0.00%+9.43%+11.72%-18.97%-60.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.6025 of 5 stars
3.61.00.00.03.23.30.0
CryoPort, Inc. stock logo
CYRX
CryoPort
3.4751 of 5 stars
4.42.00.00.01.93.30.6
MacroGenics, Inc. stock logo
MGNX
MacroGenics
4.0982 of 5 stars
3.23.00.04.41.42.50.6
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
1.9156 of 5 stars
3.40.00.00.02.73.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.25
Buy$22.00250.32% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0048.45% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$5.71380.19% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.71
Moderate Buy$41.25286.24% Upside

Current Analyst Ratings Breakdown

Latest MGNX, AURA, CYRX, and RNAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
5/23/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
5/20/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
5/14/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.00
5/14/2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$6.00 ➝ $5.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/8/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$41.00 ➝ $40.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.63N/AN/A$7.44 per share1.00
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.96M0.50N/AN/A$1.85 per share0.64
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$38.91M7.12N/AN/A($0.27) per share-39.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%8/5/2025 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$77.42M-$52.83N/AN/AN/A-510.72%N/A-7.01%8/6/2025 (Estimated)

Latest MGNX, AURA, CYRX, and RNAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.47-$0.55-$0.08-$0.55N/AN/A
5/13/2025Q1 2025
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million
5/8/2025Q1 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
11.06
11.06
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
3.28
3.11
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
12.34
12.34

Institutional Ownership

CompanyInstitutional Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.40%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.00%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
60.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5050.27 million47.55 millionNot Optionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
43063.09 million54.89 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6425.95 million10.30 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Comments on RNAC FY2026 Earnings
Cartesian Therapeutics management to meet with BTIG
BCMA prospect scores in Cartesian MG phase IIb

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.28 -0.01 (-0.16%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.30 +1.02 (+16.24%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.41 +0.12 (+1.65%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.01 (+0.13%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$1.19 -0.08 (-6.30%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.18 -0.01 (-0.84%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$10.68 -0.78 (-6.81%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$15.00 +4.32 (+40.45%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.